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identify any instances of the variant (A) allele. We vali-
dated our genotyping assay by using genomic DNA
from individuals representing all genotypes in the origi-
nal report (DNA generously provided by M. Caron).
These samples displayed the anticipated genotypes in
our assay, consistent with those reported by Zhang et al.
The GRAD sample consists of 1023 individuals with
a broad ethnic representation (57% European American,
14% Hispanic, 13% African American, 6% Asian, and
10% Other). All GRAD subjects were assessed in semi-
structured interviews and met DSM-IV criteria for major
depression. The diagnosis of major depression was
confirmed by using the diagnostic interview for genetic
studies (DIGS) depression module. According to the re-
port by Zhang et al. for the depressed subjects in their
association analysis, we would have expected a fre-
quency for the variant (1463A) allele of roughly 0.07, or
72 occurrences. The GRAD sample has high power to
identify variant alleles with frequencies >0.005.
Our failure to find the A allele of G1463A in the GRAD
sample suggests that this mutation is quite rare in human
populations, even when focusing on samples consisting
of subjects with major depression. As reported by Zhang
et al., 1463A has a marked effect on the activity of TPH2
and might therefore play a role in rare, familial forms of
depression, but its absence from the GRAD sample sug-
gests that it does not play a substantial role in the popu-
lation prevalence of major depressive disorder.
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The TPH2 G1463A polymorphism that we recently re-
ported (Zhang et al., 2005) has raised interest amongseveral research groups. This G1463A polymorphism
was identified in several individuals within a small cohort
of patients with unipolar major depression (n = 87). This
coding missense mutation (R441H) causes an w80%
loss of function in the neuronal-specific TPH2, which
could have significant physiological consequence on
brain serotonin synthesis (Zhang et al., 2004). We con-
cluded that such mutation might provide a potential
mechanism underlying dysfunction in serotonin neuro-
transmission but that further genetic studies would be
needed to investigate the inheritance and penetrance
of this polymorphism in unipolar major depression.
Originally, we identified the G1463A polymorphism in
an individual by direct sequencing. Subsequently, sev-
eral more individuals carrying this mutation were identi-
fied in a cohort of unipolar major depression by allele-
specific ARMS-PCR (Zhang et al., 2005). To further
validate the presence of the mutation in these individu-
als, amplification of a 720 bp PCR product (forward: 50-
ATGCCTTATCACCACCTTCC and reverse: 50-TTAGAT
CTGAAAAAGAAAAGGGC) was performed. PCR prod-
ucts were purified and genotyped by sequence analysis
on both strands. Furthermore, the G1463A polymor-
phism was subsequently confirmed in one of our sam-
ples by Zhou et al. (2005) and Glatt et al. (2005).
In the accompanying letters, Van Den Bogaert et al.
(2005), Glatt et al. (2005), and Zhou et al. (2005) report
that they failed to identify this mutation in several other
depression cohorts, pointing to the rarity of this mutation
compared to its apparent high frequency in our study.
The most plausible explanation for this difference is
that the unipolar major depression cohort we had access
to represents a unique and different cohort of depression
patients as compared to the other groups’ cohorts. The
subjects in our study (n = 87) were 60 years of age or
older, and they were recruited from either our inpatient
program or through our mood disorder program. Most
of the patients were severely ill, and many were refrac-
tory to treatment. Interestingly, 5 of the 9 subjects carry-
ing the G1463A polymorphism were treated with electro-
convulsive therapy (ECT), while only 16 subjects in this
cohort of 87 received ECT. Therefore, the G1463A poly-
morphism may be present in a subset of unipolar major
depression associated with severe symptoms that are
resistant to treatment. ECT is relatively rarely used, and
the fact that a high proportion of these subjects had ECT
raises the possibility that this mutation may reflect a very
small subset of very ill, refractory depressed patients.
Unipolar major depression is a complex heteroge-
neous mood disorder with markedly different clinical
profiles and responses to drug treatment (Lesch, 2004;
DSM IV), and may also represent disorders with different
endophenotypes (Hasler et al., 2004). Genetic and envi-
ronmental as well as biochemical influences are thought
to underlie the manifestations of depression (Hasler
et al., 2004; Lesch, 2004; DSM IV). Numerous studies
have indicated that depression is a polygenic disorder
associated with polymorphism(s) in several genes, in-
cluding the serotonin transporter, serotonin receptors,
the vesicular monoamine transporter, and monoamine
oxidases, as well as TPH1 and TPH2. Two hypotheses
have been suggested to explain the genetic basis of
polygenic disorders: the common disease/common var-
iant (CD/CV) hypothesis, where disease susceptibility
Neuron
706variants are common in the population, and the common
disease/rare variant (CD/RV) hypothesis with large num-
bers of rare variants at many loci (Wright et al., 2003).
To support the CD/RV hypothesis, it is noteworthy that
495 mutations, including 307 missense mutations, have
beenreported inphenylalaninehydroxylase (PAH),which
cause various degrees of phenylketonuria (PKU), a disor-
der with an incidence of 1 per 15,000 in the US (Pey et al.,
2003). PAH and TPH2 belong to the same family of
enzymes that share considerable structural and se-
quence similarities. Strikingly, the G1463A polymor-
phism (R441H) identified in our study corresponds to the
most common and severe mutation (R408W) in PKU pa-
tients. Another example is the more than 100 missense
mutations in superoxide dismutase-1 (SOD1) identified
in amyotrophic lateral sclerosis (ALS), a disorder with a
frequency of 4–6 per 100,000, yet only 2%–3% of ALS
patients carry SOD1 mutations (Bendotti and Carri,
2004). It is unlikely that the R441H mutation alone will
provide the genetic basis for all cases of depression
that affects over 20 million people in the US at any given
time with a prevalence of 2%–19% within the general
populations (Lesch, 2004; DSM IV). Rather, the R441H
mutation in TPH2 may represent a rare mutation that
could be important for a subtype of severe depression.
In addition to the R441H mutation in human TPH2 that
we reported (Zhang et al., 2005), other missense muta-
tions in TPH2 (S41Y, R55C, P206S, A328V, and D479E)
have been deposited (Accession numbers rs2887147,
rs7488262, and rs17110563) or reported by Zhou et al.
(2005), but have not yet been characterized functionally.
Moreover, additional missense mutations in TPH2 have
been identified in our laboratory and are currently being
characterized (Zhang et al., 2005). In inbred mice, a
P447R mutation in Tph2 has been identified to translate
inanw50%decrease inbrainserotoninsynthesis (Zhang
et al., 2004). It is likely that additional functional muta-
tions in TPH2 will be identified and that the presence of
multiple susceptibility genes and/or multiple mutations
in a single gene may contribute to the polygenic nature
and wide range of clinical manifestations of depression.
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